Top Markets
Coin of the day
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc.

THRX
Classifica tra le azioni #19949
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on... Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Prezzo delle azioni
$4.06
Ultima sincronizzazione: 2024-02-23
Capitalizzazione di mercato
$145.61M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Theseus Pharmaceuticals, Inc. (THRX)

Categoria

Rapporto P/B per Theseus Pharmaceuticals, Inc. (THRX)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Theseus Pharmaceuticals, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Theseus Pharmaceuticals, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH